Zeria Pharmaceutical Co (TSE:4559) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4559 Zeria Pharmaceutical Co Ltd TSE:4559
71 GF Score
Price 円2,018.00
GF Value 円2,487.13
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Zeria Pharmaceutical Co  (TSE:4559) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio Related Terms


Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio Chart

Zeria Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.50 1.68 1.54 1.50 1.38

Zeria Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.31 1.32 1.37 1.25

TSE:4559 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zeria Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4559
71GF Score
Zeria Pharmaceutical Co Ltd TSE:4559
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zeria Pharmaceutical Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Zeria Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Zeria Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=486.589/113.6000*113.6000
=486.589

Current CPI (Jun. 2026) = 113.6000.

Zeria Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 297.866 98.000 345.281
201612 314.642 98.400 363.245
201703 298.195 98.100 345.310
201706 300.824 98.500 346.940
201709 319.109 98.800 366.911
201712 338.774 99.400 387.170
201803 295.774 99.200 338.709
201806 303.127 99.200 347.129
201809 303.795 99.900 345.457
201812 336.625 99.700 383.557
201903 301.914 99.700 344.006
201906 318.202 99.800 362.202
201909 327.252 100.100 371.387
201912 344.215 100.500 389.083
202003 304.829 100.300 345.250
202006 275.223 99.900 312.966
202009 277.121 99.900 315.125
202012 322.014 99.300 368.387
202103 271.062 99.900 308.235
202106 297.232 99.500 339.352
202109 333.499 100.100 378.476
202112 365.989 100.100 415.348
202203 322.160 101.100 361.992
202206 367.972 101.800 410.625
202209 394.292 103.100 434.448
202212 408.182 104.100 445.432
202303 377.800 104.400 411.093
202306 415.255 105.200 448.412
202309 416.829 106.200 445.874
202312 481.870 106.800 512.551
202403 403.946 107.200 428.062
202406 486.751 108.200 511.044
202409 475.657 108.900 496.186
202412 507.056 110.700 520.339
202503 511.297 111.100 522.802
202506 442.151 111.700 449.672
202509 464.414 112.000 471.048
202512 547.109 113.000 550.014
202603 569.020 112.700 573.564
202606 486.589 113.600 486.589

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Zeria Pharmaceutical Co (TSE:4559) Overvalued in 2026?

Based on GuruFocus' analysis, Zeria Pharmaceutical Co stock appears to be undervalued. The current stock price of 円2,018.00 is trading 18.9% below its estimated GF Value™ of 円2,487.13. GuruFocus considers Zeria Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4559:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円2,487.13 vs. price of 円2,018.00 (18.9% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the TSE:4559 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zeria Pharmaceutical Co Business Description

Address 10-11, Nihonbashi Kobuna-cho, Tokyo, JPN, 103-8351
Zeria Pharmaceutical Co Ltd is a Japanese pharmaceutical company. The company through its subsidiaries engages in two business divisions which include ethical pharmaceutical products and consumer healthcare products business division. It principally manufactures, sells, imports and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, reagents, cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, and health equipment.
71GF Score

Get the complete analysis for TSE:4559

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,018.00
Price
円2,487.13
GF Value